Company profile: Coordination Pharma
1.1 - Company Overview
Company description
- Provider of nanoparticle-based anticancer therapies, including CPI-100, which delivers immunostimulatory chemotherapeutic combinations directly to tumors. Offers the NCP platform using nanoscale coordination polymers to develop products targeting solid tumors, and seeks partnership opportunities to enhance current cancer immunotherapies.
Products and services
- NCP platform: A custom-engineered technology employing nanoscale coordination polymers to architect anticancer products, targeting solid tumors effectively and enabling development of NCP formulations for tumor-directed drug assemblies
- CPI-100: A tumor-targeted nanoparticle-based drug engineered to deliver immunostimulatory chemotherapeutic combinations directly to tumors for cancer treatment, concentrating combination agents at tumor sites via nanoscale delivery
- Partnership Opportunities: An NCP-based collaboration initiative that offers partnerships around its NCP formulations to enhance current cancer immunotherapies, enabling joint efforts to integrate nanoscale coordination polymer products with established immunotherapy regimens
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Coordination Pharma
Kronos Bio
HQ: United States
Website
- Description: Provider of oncology therapies that modulate historically undruggable cancer targets. Pipeline includes KB-0742, a CDK9 inhibitor in phase 1/2 for MYC-dependent tumors, and KB-9558 targeting the p300 KAT domain for multiple myeloma. Offers a Small Molecule Microarray screening platform for transcription factor binding assays and a discovery collaboration with Genentech.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kronos Bio company profile →
CoStim
HQ: United States
Website
- Description: Provider of antibody agents for cancer treatment and urban regeneration, construction, energy, and digital solutions, including the ChorusLife smart human district, general contracting (Impresa Percassi), construction envelope design and manufacturing (Gualini), global energy services (Elmet), and the GSM Platform for sustainable urban transformation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CoStim company profile →
Atrin Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical discovery and development for innovative cancer treatments. The privately held company, based in Doylestown, PA, is engaged in the discovery and development of treatments for cancer, with its most advanced program focused on a new class of highly specific compounds.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atrin Pharmaceuticals company profile →
Living Pharma
HQ: United States
Website
- Description: Provider of Personalized CAR T Cell Therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Living Pharma company profile →
Northern Biologics
HQ: Canada
Website
- Description: Provider of state-of-the-art antibody discovery targeting novel and challenging oncology and fibrosis targets, developing therapeutic antibody candidates derived from a phage display platform developed and refined by world-leading researchers at the University of Toronto.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Northern Biologics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Coordination Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Coordination Pharma
2.2 - Growth funds investing in similar companies to Coordination Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Coordination Pharma
4.2 - Public trading comparable groups for Coordination Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →